Summary: Standard incubation procedures for carrying out microsomal assays involve the use of less than 1% w/v organic solvents to minimize the potential inhibitory effects of organic solvents on metabolic activity. This presents a practical limitation for poorly soluble xenobiotics, which cannot be incubated at concentrations high enough to obtain a V max , and therefore subsequent values for K m and Cl int cannot be calculated. Our goal was to study the application of a variety of pharmaceutical excipients to aid the solubilization of compounds in vitro in glucuronidation incubations, without affecting the reaction kinetics. In vitro glucuronidation incubations were carried out in human liver microsomes with 4-methylumbelliferone (4-MU) and the kinetics of 4-MU glucuronidation in the presence of excipients were compared to that in control incubations without any excipients. In addition, IC 75 values were calculated for each excipient. We observed that HPBCD (Hydroxypropyl-¢-cyclodextrin) may be employed in in vitro glucuronidation incubations up to 0.5% w/v without affecting the Cl int of 4-MU. Although NMP (N-methyl-2-pyrrolidone) and DMA (N,N-dimethylacetamide); showed low IC 75 values approximately 0.1% w/v each, neither excipients altered the Cl int of 4-MUG (4-methylumbelliferyl-¢-D-glucuronide) formation. Our studies point toward possible applications of pharmaceutical excipients to carry out in vitro glucuronidation of substrates with poor aqueous solubility, in order to estimate Cl int and subsequently scaled organ clearance values.
Introduction
Uridine diphosphoglucuronosyl transferases ¤UGTs¥ are microsomal enzymes that carry out transfer of glucuronic acid to various functional groups in xenobiotics and endobiotics. 1¥ In vitro incubations to estimate glucuronidation are carried out in microsomes from various tissues, predominantly liver. Standard incubation procedures for carrying out microsomal assays recommend less than one percent organic solvents. 2¥ Organic solvents usually employed initially to dissolve the substrate and alamethicin, a pore forming peptide, add up nearly to 1% w/v. Experiments aimed at characterization of glucuronidation activity in liver microsomal preparations from humans or any other species have revealed high K m values for glucuronidation reactions. 3¥ Consequently, substrates that have low aqueous solubility cannot be incubated at concentrations high enough to attain maximal reaction velocity ¤V max ¥. Subsequently, values for affinity constant ¤K m ¥ and intrinsic clearance ¤Cl int ¥, calculated as ¤V max ¥ normalized to K m cannot be accurately determined. Studies have shown that organic solvents like methanol, DMSO ¤Dimethyl sulfoxide¥, acetonitrile, ethanol and acetone 4®6¥ may result in moderate to high inhibition of glucuronidation in in vitro assays. The effects of varying specific incubation conditions on in vitro glucuronidation activity have also been previously examined. 7¥ The objective of the current investigation was to evaluate whether low concentrations of pharmaceutical excipients may be used in glucuronidation incubations in order to obtain better estimates of V max and K m . To test this hypothesis we screened a number of organic solvents and pharmaceutical excipients at 0.1% w/v and 1% w/v in UGT incubations containing 25 µM and 250 µM 4-MU ¤4-methylumbelliferone¥, a probe substrate for multiple UGTs that has been well studied for its glucuronidation kinetics.
8®10¥ Based on results of the screening experiments, we conducted in vitro glucuronidation incubations in HLMs ¤human liver microsomes¥ with a few promising excipients. Furthermore, we carried out inhibition assays with excipients at 100 µM 4-MU concentration to estimate a maximal concentration for a given excipient that may be used in glucuronidation assays. The present investigation illustrates applications of pharmaceutical excipients for performing in vitro glucuronidation of endobiotics and/or xenobiotics.
Materials and Methods
Chemicals: MgCl 2 ¤magnesium chloride¥, D-saccharolacone, alamethicin and UDPGA ¤uridine 5$-diphosphoglucuronic acid¥ were purchased from Sigma-Aldrich ¤St.Louis, MO¥. Solutol ¤HS 15¥ and cremophor ¤EL¥ were purchased from BASF ¤Ludwigshafen, Germany¥. HPBCD ¤Hydroxy-propyl-Ç-cyclodextrin¥ was purchased from Sigma Aldrich Co. ¤St Louis, MO, USA¥. Pooled HLM ¤20 mg/mL, pooled lot #20¥ were purchased as a 15 donor human microsomal pool from CellzDirect ¤Austin, TX, USA¥. Reagent grade propylene glycol, NMP ¤N-methyl-2-pyrrolidone¥ and DMA ¤N,N-dimethylacetamide¥, analytical grade formic acid, DMSO, ethanol, isopropyl alcohol and acetic acid, along with mass spectrometry grade acetonitrile, methanol were purchased through Fisher Scientific ¤Fair Lawn, NJ, USA¥.
In vitro incubations with HLMs: In vitro glucuronidation incubations were carried out by modification of previously reported methods.
11,12¥ Incubations for each substrate concentration were carried out in duplicate ¤n © 2¥. HLMs ¤0.5 mg of protein/mL¥ were pre-incubated in 100 mM Trizma buffer containing alamethicin ¤50 µg/mg of protein¥, 5 mM MgCl 2 , 5 mM saccharolactone, for 10 minutes on ice. The substrate, i.e. 4-MU was added thereafter. The glucuronidation reaction was initiated by addition of freshly prepared UDPGA ¤3 mM¥ to yield a final incubation volume of 0.2 mL. Incubations without UDPGA were utilized as negative controls. The final total concentration of all organic solvents, not including the pharmaceutical excipients, did not exceed one percent of total incubation volume. Pharmaceutical excipients i.e., DMA, NMP, HPBCD, cremophor, PEG200 ¤Polyethyleneglycol 200¥, PEG400 ¤Polyethyleneglycol 400¥, solutol were added at the time of addition of 4-MU. DMSO was utilized as a negative excipient control. The reaction was carried out for 30 minutes, at 37ôC in an Eppendorf Thermomixer ¬ ¤Eppendorf North America, Westbury, NY¥, shaking at 300 rpm. The reaction was stopped by addition of chilled acetonitrile, followed by centrifugation at 9,000 ' g for 5 minutes. For initial screening studies, several organic solvents and pharmaceutical excipients were screened for their effect on 4-MU glucuronidation at 25 µM and 250 µM substrate concentrations ¤Fig. 2¥. For the studies conducted to determine kinetic parameters ¤K m and V max ¥, the concentration range of 4-MU was set from 1 µM to 2 mM ¤Fig. 3¥. Pharmaceutical excipients, DMA, NMP, HPBCD, cremophor, PEG200, PEG400 and solutol were added at the time of addition of 4-MU, such that the final concentration of each excipient at each substrate concentration was 0.1% w/v. Based on the results from screening experiments ¤Fig. 1¥, HPBCD was the only excipient tested additionally, at 0.5% w/v and 1% w/v ¤Fig. 3¥. Estimations of IC 75 values for 4-MU glucuronidation in the presence of excipients were carried out at 100 µM 4-MU concentration, a value bracketed in the linear range of 4-MUG ¤4-methylumbelliferyl-Ç-D-glucuronide¥ formation in HLMs ¤human liver microsomes¥ ¤Fig. 2¥. Initial experiments were performed with 7-HCG as an internal standard initially; however, results from LC-MS/MS method validation studies did not necessitate its utilization and was later discontinued ¤data not shown¥.
LC-MS/MS Assay for 4-MUG determination: 4-MUG was analyzed by LC-MS/MS on an Applied Biosystems/MDS Sciex API 4000 ¬ mass spectrometer ¤Framing- ham, MA, USA¥ configured with Agilent 1100 ¬ binary pumps ¤Santa Clara, CA, USA¥ and a CTC PAL autosampler ¤Leap Technolgies, Carrboro, NC, USA¥. A chromatographic separation was performed on a BETASIL Phenyl column ¤2.1 ' 50 mm, 3µ¥ ¤Thermo Electron Corporation, Waltham, MA, USA¥ maintained at 40ôC. A binary gradient comprising of mobile phase A ¤0.1% formic acid in water¥ and mobile phase B ¤0.1% formic acid in acetonitrile¥ was utilized with a flow rate of 1 mL/minute. Briefly, the gradient comprised of 5% B for 0.5 minutes; 5®90% B over 0.3 minutes; 90% B for 0.8 minutes, followed by a reequilibration step. MRM ¤multiple reaction monitoring¥ detection of 4-MU was carried out by ESI in negative ion mode using nitrogen as nebulizer, drying, and collision gas. The MS transition for 4-MUG was as follows: ¤Q1¥ m/z 351.3 and ¤Q3¥ m/z 175.3. Other optimized MS parameters were as follows: collision gas: 10; curtain gas: 10; ion source gas 1 ¤GS1¥: 60; ionspray voltage: %4500; temperature: 550ôC; declustering potential ¤DP¥: %50; entrance potential ¤EP¥: %10; collision energy: %32; collision cell exit potential: %10. All transitions were monitored in a single method with a dwell time of 100 msec for each transition. Calibration, data acquisition, and peak integration were performed using the Analyst 1.4.2 software. The limit of quantitation for 4-MUG was 5 ng/mL. Standard curves for 4-MUG were developed with 4-MUG concentrations of 5 ng/mL to 10000 ng/mL and showed an R 2 ; 0.98.
Results and Discussion
Screening for excipients: Formation of 4-MUG at 25 µM and 250 µM 4-MU is shown in Figure 1 . Experiments with no excipient, but distilled water to maintain the buffer concentration, were carried out as positive controls, whereas 5% DMSO was utilized as negative control co-solvent. Twelve pharmaceutical excipients commonly employed for formulations were screened at 0.1% w/v and 1% w/v for their effects on 4-MU glucuronidation at two substrate concentrations. These concentrations of 4-MU were selected based on previously reported kinetics of 4-MUG formation in HLMs. Control incubations carried out with 4-MU alone yielded results consistent with the literature.
4,6,10¥ At least 50% activity as compared to control ¤at either substrate concentrations¥ was set as a selection criterion for excipients to be chosen for subsequent experiments. As illustrated in Figure 1 , methanol, ethanol, isopropyl alcohol, DMSO and propylene glycol showed remarkable inhibition of 4-MU glucuronidation, and were not chosen for kinetic experiments. Incubations with PEG200 and PEG400 showed 50% or lower velocity of 4-MU glucuronidation. However, both the excipients were chosen for subsequent experiments as negative excipient controls. Some excipients such as 0.1% DMA, 0.1% DMSO, 0.1% methanol and 1% HPBCD showed a change in the velocity of 4-MUG formation at 250 µM 4-MU concentration, which is near the K m of 4-MUG formation but not at 25 µM 4-MU. Whether this may be due to competitive, uncompetitive or even mixed type inhibition where K m is documented to change, is merely a theory at this time. Further inhibition studies and characterization of reaction kinetics with these excipients are warranted to test this hypothesis.
Inhibition of 4-MU glucuronidation: Inhibition experiments were conducted with excipients namely, DMA, NMP, HPBCD, cremophor, solutol, PEG200 and PEG400 based on the results from the screening assay. Results from these experiments are depicted in Figure 2 . Velocity for 4-MUG formation at 100 µM substrate concentration, a concentration in the linear range, was set at 100%. 4-MU glucuronidation in incubations containing excipients was recorded as % activity of control, with excipient concentrations ranging from 0.1% w/v to 1% w/v for each excipient. Up to 25% variation in analytical readout due to Fig. 3 . Formation of 4-MUG in the presence of pharmaceutical excipients Michaelis-Menten kinetics are reported as means of duplicate measurements (n = 2). Cremophor, DMSO, PEG200, PEG400 and solutol showed alterations in kinetic profiles and were not best fit to Michaelis-Menten kinetics. Incubations with distilled water in order to maintain the buffer concentration were utilized as control, represent on the main plot by a dotted line. The formation of 4-MUG is also illustrated on an inserted plot.
Fig. 2. Inhibition plots depicting IC 75 values for pharmaceutical excipients
The data are represented as means of duplicate measurements (n = 2). Incubations with distilled water to maintain the buffer concentration were utilized as controls.
experimental and operational variability was indistinguishable for the control experiments, based on our experience with validation experiments such as measurement of interand intra-day variability with LC-MS assay, linearity studies with time and protein concentrations ¤data not shown¥. Therefore IC 75 values were identified to be more relevant for this experiment and computed for each pharmaceutical excipient as shown in Table 1 . HPBCD showed no inhibition up to 0.5% whereas solutol, PEG200, PEG400 and cremophor along with DMA and NMP showed marked inhibition of 4-MU glucuronidation at 0.1% w/v.
Kinetics of 4-MU glucuronidation with 0.1% excipients: Glucuronidation of 4-MU has been widely studied, and is reported to proceed via Michaelis-Menten kinetics.
8®10¥ Results from control experiments ¤with no excipients, but water¥ were a best fit to Michaelis-Menten kinetics. Glucuronidation of 4-MU was found to progress with a V max of 33 nmoles/min/mg protein and a K m of 0.21 mM, substantiating the literature reports. Therefore, the Cl int value was calculated to be 157 µL/minute/mg protein ¤Cl int © V max /K m ¥. Cl int values for 4-MUG formation in the presence of pharmaceutical excipients are reported in Table 2 . Upon comparison with the control, PEG200, PEG400, solutol and cremophor not only showed marked inhibition of 4-MU glucuronidation, but also change in the kinetic profile. The resulting V max and K m were not a best fit to Michaelis-Menten kinetics and Cl int could not be calculated from these data. This data must be interpreted with caution. Furthermore, these excipients may affect 4-MU glucuronidation by multiple mechanisms and further comprehensive experiments may be needed to assess the type of inhibition due to these excipients. However, such experiments were beyond the scope of present investigation, which focused on assessing solubilization effects of excipients.
As a consequence of positive results from the IC 75 experiments, 4-MU glucuronidation kinetics were also carried out at 0.5% w/v ¤IC 75 ¥, and 1% w/v ¤2 ' IC 75 ¥ concentrations in addition to 0.1% w/v. HPBCD did not affect 4-MU glucuronidation at 0.1% w/v and 0.5% w/v. Among other excipients tested, 0.1% DMA and 0.1% NMP surprisingly did not show any inhibition of 4-MUG formation. Our results indicate that up to 0.5% HPBCD, 0.1% DMA and 0.1% NMP may be employed in order to obtain Cl int values. However, it must be noted that appropriate controls need to be utilized when running such experiments with excipients. Moreover, such an approach needs to be further validated with poorly soluble compounds that have been well studied. The excipient concentrations utilized in the present investigation were purely aimed at studying the solubilization effect on a substrate without affecting the glucuronidation reaction. It is extremely unlikely that such high excipient concentrations will be observed in vivo after administration of corresponding formulations or dosing forms. Therefore, the present data are not recommended to be interpreted from an in vivo experimental perspective.
In summary, this report illustrates the application of a variety of pharmaceutical excipients for in vitro glucuronidation incubations. This approach may be applied as a technique to estimate the maximal velocity and the affinity constant of poorly soluble substrates in a liver microsomal model for glucuronidation reactions by UGTs. These parameters will enable estimation of Cl int for a given glucuronidation reaction. Realistic estimation of Cl int values will further allow for assessment of scaled hepatic or organ clearances. This may particularly be of importance for xenobiotics that have glucuronidation as their major clearance pathway. Such an approach may be extrapolated to other drug metabolizing enzymes. Evaluation of this experiments, 4-MU alone was run at three concentrations¯0.5% w/v ¤IC 75 ¥, and 1% w/v concentrations in addition to 0.1% w/v. Cremophor, DMSO, PEG200, PEG400 and solutol showed alteration of kinetic profiles. ¤* denotes that V max and K m values for these excipients were not a best fit to Michaelis-Menten kineitcs, and must be interpreted with caution.¥ approach with recombinant enzyme systems and for compounds with poor solubility is currently underway in our laboratory.
